President Donald Trump’s continued resistance to use his emergency powers to compel companies to produce medical supplies needed in the fight against the novel coronavirus has drawn a bipartisan chorus of criticism. Experts say it could jumpstart domestic production, though global constraints may limit how quickly it could make an impact. Trump has yet to put the Korean War-era Defense Production Act (DPA) into practice, instead leaving private companies to volunteer their production lines and states to compete for contracts of masks, ventilators, gowns and other essential supplies to treat patients suffering from COVID-19. But as hard-hit states and hospitals have said they are not getting the supplies they need from the federal government or private companies’ donation, experts say that elevating the federal response by compelling certain aspects of production could better coordinate the relatively ad-hoc production shifts and donations thus far. “The private sector is responding with some action here, but it couldn’t hurt to have the federal government trying to light a fire under the process,” Ethan Harris, head of global economics research for Bank of America, told ABC News. Tune into ABC at 1 p.m. ET and ABC News Live at 4 p.m. ET every weekday


Continue To Full Article